Chemed Corp (CHE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Chemed Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 532.30 $ — 96% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 5.8% failed
- More than 10% revenue growth is expected for the coming year 6.2% failed
- Share count grows by less than 3% a year -1.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 16.9% failed
- Gross margin at 40% or higher and without meaningful erosion 30.0% failed
- Goodwill from acquisitions does not grow faster than revenue 40.7% passed
- Net debt below twice EBITDA 0.2 x EBITDA passed
- Operating cash flow covers the profits of the last three years 296 m passed
- Return on capital at 15% or higher, or up versus two years ago 25.0% passed
- Insiders hold at least 10% or are net buyers 2.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 3.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 25.52 | 25.39 – 25.62 | 2,721 | 18.4% | 4 |
| 12/31/2027 | 27.53 | 27.35 – 27.73 | 2,883 | 7.9% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 6.02 | 2.20 | 640 | 9.20 | 14.10 | 165 | 152 |
| 2025: Q1 | 4.86 | 14.70 | 647 | 9.80 | 11.10 | 33 | 20 |
| 2025: Q2 | 3.59 | -22.70 | 619 | 3.80 | 8.50 | 139 | 123 |
| 2025: Q3 | 4.42 | -12.00 | 625 | 3.10 | 10.30 | 83 | 66 |
| 2025: Q4 | 5.48 | -9.00 | 639 | -0.10 | 12.00 | 134 | 117 |
| 2026: Q1 | 4.85 | -0.20 | 658 | 1.60 | 10.10 | 88 | 71 |
| 2026: Q2 | 5.13 | 42.90 | 673 | 8.80 | 10.10 | 85 | 69 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,577 | 179 | 109 | 6.48 | 135 | 524 | 880 |
| 2017 | 1,667 | 113 | 98 | 5.86 | 163 | 540 | 920 |
| 2018 | 1,783 | 244 | 206 | 12.23 | 287 | 591 | 976 |
| 2019 | 1,939 | 257 | 220 | 13.31 | 301 | 727 | 1,268 |
| 2020 | 2,080 | 390 | 319 | 19.48 | 489 | 901 | 1,435 |
| 2021 | 2,139 | 343 | 269 | 16.85 | 309 | 623 | 1,343 |
| 2022 | 2,135 | 344 | 250 | 16.53 | 310 | 799 | 1,442 |
| 2023 | 2,264 | 341 | 273 | 17.93 | 330 | 1,108 | 1,668 |
| 2024 | 2,431 | 366 | 302 | 19.89 | 418 | 1,119 | 1,669 |
| 2025 | 2,530 | 338 | 265 | 18.42 | 388 | 979 | 1,640 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Chemed Corporation erbringt Hospiz- und Palliativpflegedienste für Patienten über ein Netzwerk aus Ärzten, Krankenpflegern, Pflegehelfern, Sozialarbeitern, Seelsorgern und Freiwilligen, hauptsächlich in den USA. Das Unternehmen ist in zwei Segmenten tätig: VITAS und Roto-Rooter…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 15,811 |
| Headquarters | Cincinnati, OH |
| Address | 2600 First Financial Center, 45202-4726 Cincinnati, United States |
| Phone | 513 762 6690 |
| Website | chemed.com |
| IPO Date | 3. May 1973 |
| ISIN | US16359R1032 |
| Stock Split | 2:1 on 05/12/2005 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kevin J. McNamara | CEO, President & Director | 1954 |
| Michael D. Witzeman CPA, MBA | Executive VP, Controller, Principal Accounting Officer & CFO | 1971 |
| Brian C. Judkins J.D. | VP, Secretary & Chief Legal Officer | 1981 |
| Spencer S. Lee | Executive Vice President | 1956 |
| Thomas C. Hutton J.D. | VP & Director | 1951 |
| Joel L. Wherley | Executive VP and President & CEO of VITAS Healthcare | 1965 |
| Lisa A. Reinhard | VP, Chief Administrative Officer & Assistant Secretary | 1973 |
| Sherri Warner | Director of Investor Relations | – |
| Nathan J. McNamara | VP & Chief Strategy Officer | 1988 |
| Holley R. Schmidt | Vice President & Assistant Controller | 1972 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.